ATE366308T1 - Immunostimulierende oligodeoxyribonuklein moleküle - Google Patents
Immunostimulierende oligodeoxyribonuklein moleküleInfo
- Publication number
- ATE366308T1 ATE366308T1 AT02748709T AT02748709T ATE366308T1 AT E366308 T1 ATE366308 T1 AT E366308T1 AT 02748709 T AT02748709 T AT 02748709T AT 02748709 T AT02748709 T AT 02748709T AT E366308 T1 ATE366308 T1 AT E366308T1
- Authority
- AT
- Austria
- Prior art keywords
- deoxyribosepurine
- deoxycytosine
- deoxyinosine
- deoxyguanosine
- deoxyadenosine
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 2
- RPFPNGBGDKGFRI-XLPZGREQSA-N 9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-methyl-3h-purin-6-one Chemical compound C12=NC(C)=NC(O)=C2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 RPFPNGBGDKGFRI-XLPZGREQSA-N 0.000 abstract 2
- FERYXNKLCFJNMG-QJPTWQEYSA-N (2r,3s,5r)-2-(hydroxymethyl)-5-[6-(3-methylbut-3-enylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NCCC(=C)C)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 FERYXNKLCFJNMG-QJPTWQEYSA-N 0.000 abstract 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 abstract 1
- COVHWGAKPGOZBI-QJPTWQEYSA-N [(2r,3s,5r)-3-hydroxy-5-[6-(3-methylbut-3-enylamino)purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(NCCC(=C)C)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 COVHWGAKPGOZBI-QJPTWQEYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000004712 monophosphates Chemical class 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Laminated Bodies (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT8052001 | 2001-05-21 | ||
| PCT/EP2002/005448 WO2002095027A2 (en) | 2001-05-21 | 2002-05-17 | Immunostimulatory oligodeoxynucleic molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE366308T1 true ATE366308T1 (de) | 2007-07-15 |
Family
ID=3681210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02748709T ATE366308T1 (de) | 2001-05-21 | 2002-05-17 | Immunostimulierende oligodeoxyribonuklein moleküle |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7858588B2 (de) |
| EP (2) | EP1390494A2 (de) |
| JP (2) | JP2005501004A (de) |
| CN (1) | CN1526016A (de) |
| AT (1) | ATE366308T1 (de) |
| AU (1) | AU2002320762B2 (de) |
| CA (2) | CA2447793A1 (de) |
| DE (1) | DE60221004T2 (de) |
| ES (1) | ES2288555T3 (de) |
| WO (2) | WO2002094845A2 (de) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7378234B2 (en) | 2002-09-13 | 2008-05-27 | Intercell Ag | Method for isolating hepatitis C virus peptides |
| US7528223B2 (en) | 2002-07-24 | 2009-05-05 | Intercell Ag | Antigens encoded by alternative reading frames from pathogenic viruses |
| US7704514B2 (en) | 2003-03-24 | 2010-04-27 | Intercell Ag | Vaccines |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050250716A1 (en) * | 2001-12-07 | 2005-11-10 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| DE102004049223A1 (de) * | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
| JP2007045730A (ja) * | 2005-08-09 | 2007-02-22 | Nitto Denko Corp | 免疫誘導能増強方法 |
| EP1924284A1 (de) * | 2005-09-14 | 2008-05-28 | Hartmann, Gunther | Zusammensetzungen mit immunstimulatorischen rna-oligonucleotiden und verfahren zur herstellung dieser rna-oligonucleotide |
| EP2292647A3 (de) | 2006-07-07 | 2011-06-08 | Intercell AG | Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür |
| EP2289906A1 (de) | 2006-09-15 | 2011-03-02 | Intercell AG | Borrelia-Antigene |
| EP1923069A1 (de) | 2006-11-20 | 2008-05-21 | Intercell AG | Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen |
| EP2266592A3 (de) | 2007-01-12 | 2012-08-08 | Intercell AG | Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür |
| CA2685805A1 (en) | 2007-05-02 | 2008-11-13 | Intercell Ag | Klebsiella antigens |
| EP2012122A1 (de) | 2007-07-06 | 2009-01-07 | Medigene AG | Strukturproteine von mutierten Parvoviren als Impfstoffe |
| EP2158211B1 (de) | 2007-05-31 | 2016-08-10 | Medigene AG | Mutiertes strukturprotein eines parvovirus |
| EP2511291A3 (de) | 2007-06-18 | 2012-11-07 | Intercell AG | Chlamydia-Antigene |
| AU2009226949A1 (en) | 2008-03-17 | 2009-09-24 | Intercell Ag | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| ES2569907T3 (es) | 2008-06-27 | 2016-05-13 | Zoetis Services Llc | Composiciones adyuvantes novedosas |
| EP2424882A2 (de) | 2009-02-05 | 2012-03-07 | Intercell AG | Gegen e.-faecalis schützende peptide, verfahren und anwendungen, die damit in zusammenhang stehen |
| EP2405938A2 (de) | 2009-02-13 | 2012-01-18 | Intercell AG | Nicht typisierbare haemophilus influenza-antigene |
| EP2308896A1 (de) | 2009-10-09 | 2011-04-13 | Sanofi-aventis | Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten |
| PH12012500564A1 (en) | 2009-10-09 | 2012-10-22 | Sanofi Sa | Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving the same |
| EP2319871A1 (de) | 2009-11-05 | 2011-05-11 | Sanofi-aventis | Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten |
| JP5808082B2 (ja) * | 2010-04-30 | 2015-11-10 | 株式会社Adeka | 細胞への水溶性高分子量物質の導入方法及び導入剤 |
| KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
| AR082925A1 (es) | 2010-09-08 | 2013-01-16 | Medigene Ag | Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados |
| KR20200039025A (ko) | 2013-09-19 | 2020-04-14 | 조에티스 서비시즈 엘엘씨 | 유성 아쥬반트 |
| AU2014322046B2 (en) * | 2013-09-20 | 2021-02-04 | Daiichi Sankyo Company, Limited | Complex containing oligonucleotide having immunopotentiating activity and use thereof |
| MX391930B (es) | 2015-01-16 | 2025-03-21 | Zoetis Services Llc | Vacuna contra la fiebre aftosa. |
| CN112074295A (zh) | 2018-02-16 | 2020-12-11 | 2A制药公司 | 用于治疗自身免疫性疾病的细小病毒结构蛋白 |
| EP3527223A1 (de) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutiertes parvovirus-strukturprotein |
| KR20220010478A (ko) | 2019-05-20 | 2022-01-25 | 발네바 에스이 | 기도 감염의 치료 또는 예방용 서브유닛 백신 |
| WO2020240268A1 (en) | 2019-05-31 | 2020-12-03 | Universidad De Chile | An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec) |
| WO2022074061A1 (en) | 2020-10-07 | 2022-04-14 | Valneva Sweden Ab | Cholera vaccine formulation |
| KR20230167017A (ko) | 2021-04-09 | 2023-12-07 | 발네바 에스이 | 인간 메타뉴모 바이러스 백신 |
| WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3725545A (en) | 1971-02-03 | 1973-04-03 | R Maes | Enhancement of antibody production by nucleic acid-polycation complexes |
| US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO1998016247A1 (en) | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1003531B1 (de) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| WO1998055609A1 (en) | 1997-06-06 | 1998-12-10 | The Regents Of The University Of California | Inhibitors of dna immunostimulatory sequence activity |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| EP1077708A1 (de) | 1998-05-06 | 2001-02-28 | University Of Iowa Research Foundation | Methoden zur preventiven und therapeutischen behandlung von parasitären infektionen und damit verbundener krankheiten mittels cpg oligonukleotiden |
| US6403102B1 (en) * | 1998-10-29 | 2002-06-11 | Connaught Laboratories Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| AT408721B (de) * | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
| AU2001257366B2 (en) | 2000-05-01 | 2006-03-16 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| HU228264B1 (en) * | 2000-06-08 | 2013-02-28 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| WO2002069369A2 (en) * | 2000-12-08 | 2002-09-06 | Coley Pharmaceutical Gmbh | Cpg-like nucleic acids and methods of use thereof |
| US20050250716A1 (en) | 2001-12-07 | 2005-11-10 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
-
2002
- 2002-05-17 EP EP02745299A patent/EP1390494A2/de not_active Withdrawn
- 2002-05-17 WO PCT/EP2002/005447 patent/WO2002094845A2/en not_active Ceased
- 2002-05-17 US US10/478,771 patent/US7858588B2/en not_active Expired - Fee Related
- 2002-05-17 AT AT02748709T patent/ATE366308T1/de active
- 2002-05-17 CA CA002447793A patent/CA2447793A1/en not_active Abandoned
- 2002-05-17 JP JP2002591518A patent/JP2005501004A/ja not_active Withdrawn
- 2002-05-17 US US10/478,426 patent/US20050070462A1/en not_active Abandoned
- 2002-05-17 JP JP2002592489A patent/JP4188092B2/ja not_active Expired - Fee Related
- 2002-05-17 WO PCT/EP2002/005448 patent/WO2002095027A2/en not_active Ceased
- 2002-05-17 AU AU2002320762A patent/AU2002320762B2/en not_active Ceased
- 2002-05-17 CN CNA028116976A patent/CN1526016A/zh active Pending
- 2002-05-17 DE DE60221004T patent/DE60221004T2/de not_active Expired - Lifetime
- 2002-05-17 CA CA002448031A patent/CA2448031A1/en not_active Abandoned
- 2002-05-17 ES ES02748709T patent/ES2288555T3/es not_active Expired - Lifetime
- 2002-05-17 EP EP02748709A patent/EP1390495B1/de not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7528223B2 (en) | 2002-07-24 | 2009-05-05 | Intercell Ag | Antigens encoded by alternative reading frames from pathogenic viruses |
| US7378234B2 (en) | 2002-09-13 | 2008-05-27 | Intercell Ag | Method for isolating hepatitis C virus peptides |
| US7704514B2 (en) | 2003-03-24 | 2010-04-27 | Intercell Ag | Vaccines |
| US8784837B2 (en) | 2003-03-24 | 2014-07-22 | Valneva Austria Gmbh | Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60221004T2 (de) | 2008-03-13 |
| CA2447793A1 (en) | 2002-11-28 |
| WO2002095027A2 (en) | 2002-11-28 |
| CN1526016A (zh) | 2004-09-01 |
| EP1390495B1 (de) | 2007-07-04 |
| CA2448031A1 (en) | 2002-11-28 |
| ES2288555T3 (es) | 2008-01-16 |
| WO2002094845A2 (en) | 2002-11-28 |
| JP4188092B2 (ja) | 2008-11-26 |
| WO2002095027A3 (en) | 2003-08-21 |
| JP2005501004A (ja) | 2005-01-13 |
| JP2004530428A (ja) | 2004-10-07 |
| DE60221004D1 (de) | 2007-08-16 |
| WO2002094845A3 (en) | 2003-11-06 |
| US20050070462A1 (en) | 2005-03-31 |
| AU2002320762B2 (en) | 2006-09-21 |
| EP1390494A2 (de) | 2004-02-25 |
| US20040248831A1 (en) | 2004-12-09 |
| EP1390495A2 (de) | 2004-02-25 |
| US7858588B2 (en) | 2010-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE249839T1 (de) | Immunstimulierende oligodeoxynukleotide | |
| DE60221004D1 (de) | Immunostimulierende oligodeoxyribonuklein moleküle | |
| DE60109916D1 (de) | Modulation von oligonukleotid cpg-vermittelter immunstimulation durch modifikation der nucleoside | |
| DE69838449D1 (de) | Aminooxy-modifizierte oligonukleotide | |
| ATE154029T1 (de) | 7-deazapurin modifizierte oligonukleotide | |
| CY1108158T1 (el) | Ολιγονουκλεοτιδιο ν3'→ρ5' θειoφωσφοραμιδικα: συνθεση αυτων και χρηση | |
| DK0759927T3 (da) | Pteridinnucleotidanaloger som fluorescerende DNA prober | |
| DE60017259D1 (de) | Modulierung der durch cpg-oligonukleotide verursachten immunstimulierung durch positionsbedingte veränderung von nukleosiden | |
| BR9908537A (pt) | Copolìmeros biocompatìveis e utilização dos mesmos | |
| Okamura et al. | Proto‐urea‐RNA (Wöhler RNA) containing unusually stable urea nucleosides | |
| HUP0203914A2 (en) | High order nucleic acid based structures | |
| CY1106041T1 (el) | Καινοφανης συλλεκτινη | |
| WO2023039005A3 (en) | Modified short interfering nucleic acid (sina) molecules and uses thereof | |
| BR0312460A (pt) | Suporte sólido, processo de preparação, e, uso do mesmo | |
| DK1644389T3 (da) | Pyrinidinforbindelser med phosphonatgrupper som antivirale nukleotidanaloger | |
| JP2003012760A5 (de) | ||
| ATE242261T1 (de) | Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen | |
| WO2024097674A3 (en) | Modified short interfering nucleic acid (sina) molecules and uses thereof | |
| KR960700262A (ko) | 이합체 블록의 합성 및 그것의 올리고누클레오티드 어셈블리에의 사용 방법(synthesis of dimmer blocks and their use in assembling oligonucleotides) | |
| DE60204859D1 (de) | Verfahren zur herstellung von 2'-fluoro-beta-l-arabinofuranosylnukleosiden | |
| Hartel et al. | Substitution of Adenine by Purine‐2, 6‐diamine Improves the Nonenzymatic Oligomerization of Ribonucleotides on Templates Containing Thymidine | |
| FR2812637B1 (fr) | Nouveaux composes derives de dihydroporphyrine et leurs applications | |
| BRPI0207566B8 (pt) | processo para preparação de (e)-5-(2-bromovinil)-2'-desoxiuridina | |
| FI89705C (fi) | Hoeghaollfasta -sialonhaltiga keramer | |
| JP2022512651A5 (de) |